N Engl J Med:黑猩猩腺病毒载体埃博拉疫苗

2017-03-10 MedSci MedSci原创

在一项关于黑猩猩腺病毒载体埃博拉疫苗cAd3-EBO研究中,研究人员发现受试者对cAd3-EBO疫苗的反应原性和免疫反应是剂量依赖性的。在2×10 11颗粒单位剂量下,糖蛋白扎伊尔特异性抗体反应与涉及非人类灵长类动物的挑战研究中的疫苗诱导的保护性免疫相关,并且反应可持续持续到48周。目前,2期研究和评估cAd3-EBO的功效试验正在进行中。

最近,来自法国国家过敏症和传染病研究所的研究人员在2014年报道关于cAd3-EBO疫苗安全性和免疫原性的基础上对该疫苗在成人中的耐久性进行进一步研究。相关研究刊登于国际权威杂志new England journal of medicine上,该研究或为后期埃博拉疫苗研究提供帮助。

2014年,前所未有的埃博拉疫情促使国际社会加速预防性疫苗的使用。在此背景下,来自扎伊尔和苏丹黑猩猩物种的能够编码糖蛋白的有复制缺陷的重组腺病毒3型载体病毒疫苗(cAd3-EBO)因为其能够在非人类的灵长类动物模型中提供保护而迅速进入1期临床评估。

研究人员开展了针对cAd3-EBO的剂量递增,开放标签的1期试验。以顺序纳入二十个健康成人,每组10个,并以2×10102×1011颗粒单位剂量肌内接种疫苗。在接种后的前8周评估与安全性和免疫原性相关的初级和次级终点; 此外,在接种后48周评估疫苗耐久性。

在这项小型研究中,虽然没有发现安全问题; 然而,在接受2×1011颗粒单位剂量的两名受试者在接种后1天内发生短暂性发热。在所有20个受试者中均诱导得到糖蛋白特异性抗体; 且滴度在接受2×10 11颗粒单位剂量的组中高于在接受2×1010颗粒单位剂量的组(在第4周,扎伊尔抗原的几何平均滴度为 2037 vs. 331; P=0.001)。糖蛋白特异性T细胞反应在接受2×1011颗粒单位剂量的那些人中比在接受2×1010颗粒单位剂量的那些人中更频繁,第4周,在2×1011颗粒单位剂量组中, 10个受试者有CD4反应应答,7个有CD8反应应答,对比之下,2×1010组中10名参与者,3个受试者有CD4反应应答(P = 0.004)和2名有CD8反应应答(P = 0.07)。抗体应答耐久性的评估显示,在接受2×1011颗粒单位剂量的受试者中滴度在48周时仍保持较高水平。

研究发现,受试者对cAd3-EBO疫苗的反应原性和免疫反应是剂量依赖性的。在2×10 11颗粒单位剂量下,糖蛋白扎伊尔特异性抗体反应与涉及非人类灵长类动物的挑战研究中的疫苗诱导的保护性免疫相关,并且反应可持续持续到48周。目前,2期研究和评估cAd3-EBO的功效试验正在进行中。

原始出处:

Ledgerwood JE, DeZure AD, Stanley DA,  et al. Chimpanzee Adenovirus Vector Ebola VaccineN Engl J Med 2017; 376:928-938March 9, 2017DOI: 10.1056/NEJMoa1410863

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1645425, encodeId=ef85164542565, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Wed Apr 12 00:24:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785442, encodeId=470e1e8544224, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Nov 22 10:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702877, encodeId=98131e0287717, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Tue Oct 17 04:24:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724156, encodeId=42151e241565f, content=<a href='/topic/show?id=f9cfe09905f' target=_blank style='color:#2F92EE;'>#病毒载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70990, encryptionId=f9cfe09905f, topicName=病毒载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebd533571600, createdName=ewsr12, createdTime=Tue Aug 22 20:24:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081339, encodeId=64192081339f3, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Aug 29 05:24:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460065, encodeId=2bc1146006567, content=<a href='/topic/show?id=d44f415583a' target=_blank style='color:#2F92EE;'>#埃博拉疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41558, encryptionId=d44f415583a, topicName=埃博拉疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78136234994, createdName=yourmama, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607285, encodeId=ab48160e2855c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179174, encodeId=86e61e9174aa, content=跟进热点,信息丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Mar 11 20:52:43 CST 2017, time=2017-03-11, status=1, ipAttribution=)]
    2017-04-12 mei539
  2. [GetPortalCommentsPageByObjectIdResponse(id=1645425, encodeId=ef85164542565, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Wed Apr 12 00:24:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785442, encodeId=470e1e8544224, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Nov 22 10:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702877, encodeId=98131e0287717, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Tue Oct 17 04:24:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724156, encodeId=42151e241565f, content=<a href='/topic/show?id=f9cfe09905f' target=_blank style='color:#2F92EE;'>#病毒载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70990, encryptionId=f9cfe09905f, topicName=病毒载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebd533571600, createdName=ewsr12, createdTime=Tue Aug 22 20:24:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081339, encodeId=64192081339f3, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Aug 29 05:24:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460065, encodeId=2bc1146006567, content=<a href='/topic/show?id=d44f415583a' target=_blank style='color:#2F92EE;'>#埃博拉疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41558, encryptionId=d44f415583a, topicName=埃博拉疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78136234994, createdName=yourmama, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607285, encodeId=ab48160e2855c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179174, encodeId=86e61e9174aa, content=跟进热点,信息丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Mar 11 20:52:43 CST 2017, time=2017-03-11, status=1, ipAttribution=)]
    2017-11-22 haouestc
  3. [GetPortalCommentsPageByObjectIdResponse(id=1645425, encodeId=ef85164542565, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Wed Apr 12 00:24:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785442, encodeId=470e1e8544224, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Nov 22 10:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702877, encodeId=98131e0287717, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Tue Oct 17 04:24:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724156, encodeId=42151e241565f, content=<a href='/topic/show?id=f9cfe09905f' target=_blank style='color:#2F92EE;'>#病毒载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70990, encryptionId=f9cfe09905f, topicName=病毒载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebd533571600, createdName=ewsr12, createdTime=Tue Aug 22 20:24:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081339, encodeId=64192081339f3, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Aug 29 05:24:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460065, encodeId=2bc1146006567, content=<a href='/topic/show?id=d44f415583a' target=_blank style='color:#2F92EE;'>#埃博拉疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41558, encryptionId=d44f415583a, topicName=埃博拉疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78136234994, createdName=yourmama, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607285, encodeId=ab48160e2855c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179174, encodeId=86e61e9174aa, content=跟进热点,信息丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Mar 11 20:52:43 CST 2017, time=2017-03-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1645425, encodeId=ef85164542565, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Wed Apr 12 00:24:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785442, encodeId=470e1e8544224, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Nov 22 10:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702877, encodeId=98131e0287717, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Tue Oct 17 04:24:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724156, encodeId=42151e241565f, content=<a href='/topic/show?id=f9cfe09905f' target=_blank style='color:#2F92EE;'>#病毒载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70990, encryptionId=f9cfe09905f, topicName=病毒载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebd533571600, createdName=ewsr12, createdTime=Tue Aug 22 20:24:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081339, encodeId=64192081339f3, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Aug 29 05:24:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460065, encodeId=2bc1146006567, content=<a href='/topic/show?id=d44f415583a' target=_blank style='color:#2F92EE;'>#埃博拉疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41558, encryptionId=d44f415583a, topicName=埃博拉疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78136234994, createdName=yourmama, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607285, encodeId=ab48160e2855c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179174, encodeId=86e61e9174aa, content=跟进热点,信息丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Mar 11 20:52:43 CST 2017, time=2017-03-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1645425, encodeId=ef85164542565, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Wed Apr 12 00:24:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785442, encodeId=470e1e8544224, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Nov 22 10:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702877, encodeId=98131e0287717, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Tue Oct 17 04:24:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724156, encodeId=42151e241565f, content=<a href='/topic/show?id=f9cfe09905f' target=_blank style='color:#2F92EE;'>#病毒载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70990, encryptionId=f9cfe09905f, topicName=病毒载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebd533571600, createdName=ewsr12, createdTime=Tue Aug 22 20:24:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081339, encodeId=64192081339f3, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Aug 29 05:24:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460065, encodeId=2bc1146006567, content=<a href='/topic/show?id=d44f415583a' target=_blank style='color:#2F92EE;'>#埃博拉疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41558, encryptionId=d44f415583a, topicName=埃博拉疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78136234994, createdName=yourmama, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607285, encodeId=ab48160e2855c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179174, encodeId=86e61e9174aa, content=跟进热点,信息丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Mar 11 20:52:43 CST 2017, time=2017-03-11, status=1, ipAttribution=)]
    2017-08-29 spoonycyy
  6. [GetPortalCommentsPageByObjectIdResponse(id=1645425, encodeId=ef85164542565, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Wed Apr 12 00:24:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785442, encodeId=470e1e8544224, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Nov 22 10:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702877, encodeId=98131e0287717, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Tue Oct 17 04:24:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724156, encodeId=42151e241565f, content=<a href='/topic/show?id=f9cfe09905f' target=_blank style='color:#2F92EE;'>#病毒载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70990, encryptionId=f9cfe09905f, topicName=病毒载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebd533571600, createdName=ewsr12, createdTime=Tue Aug 22 20:24:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081339, encodeId=64192081339f3, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Aug 29 05:24:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460065, encodeId=2bc1146006567, content=<a href='/topic/show?id=d44f415583a' target=_blank style='color:#2F92EE;'>#埃博拉疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41558, encryptionId=d44f415583a, topicName=埃博拉疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78136234994, createdName=yourmama, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607285, encodeId=ab48160e2855c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179174, encodeId=86e61e9174aa, content=跟进热点,信息丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Mar 11 20:52:43 CST 2017, time=2017-03-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1645425, encodeId=ef85164542565, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Wed Apr 12 00:24:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785442, encodeId=470e1e8544224, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Nov 22 10:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702877, encodeId=98131e0287717, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Tue Oct 17 04:24:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724156, encodeId=42151e241565f, content=<a href='/topic/show?id=f9cfe09905f' target=_blank style='color:#2F92EE;'>#病毒载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70990, encryptionId=f9cfe09905f, topicName=病毒载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebd533571600, createdName=ewsr12, createdTime=Tue Aug 22 20:24:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081339, encodeId=64192081339f3, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Aug 29 05:24:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460065, encodeId=2bc1146006567, content=<a href='/topic/show?id=d44f415583a' target=_blank style='color:#2F92EE;'>#埃博拉疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41558, encryptionId=d44f415583a, topicName=埃博拉疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78136234994, createdName=yourmama, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607285, encodeId=ab48160e2855c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179174, encodeId=86e61e9174aa, content=跟进热点,信息丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Mar 11 20:52:43 CST 2017, time=2017-03-11, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1645425, encodeId=ef85164542565, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Wed Apr 12 00:24:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785442, encodeId=470e1e8544224, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Nov 22 10:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702877, encodeId=98131e0287717, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Tue Oct 17 04:24:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724156, encodeId=42151e241565f, content=<a href='/topic/show?id=f9cfe09905f' target=_blank style='color:#2F92EE;'>#病毒载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70990, encryptionId=f9cfe09905f, topicName=病毒载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebd533571600, createdName=ewsr12, createdTime=Tue Aug 22 20:24:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081339, encodeId=64192081339f3, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Aug 29 05:24:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460065, encodeId=2bc1146006567, content=<a href='/topic/show?id=d44f415583a' target=_blank style='color:#2F92EE;'>#埃博拉疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41558, encryptionId=d44f415583a, topicName=埃博拉疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78136234994, createdName=yourmama, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607285, encodeId=ab48160e2855c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Mar 12 02:24:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179174, encodeId=86e61e9174aa, content=跟进热点,信息丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Mar 11 20:52:43 CST 2017, time=2017-03-11, status=1, ipAttribution=)]
    2017-03-11 虈亣靌

    跟进热点,信息丰富

    0

相关资讯

天津:投入980万元促进12种疫苗免费接种

天津市满1周岁儿童可免费接种水痘疫苗,14万适龄儿童因此受益。

全球被忽视疾病创新基金:埃博拉疫苗研究一枝独秀

根据澳大利亚悉尼一家健康政策分析公司“政策治疗研究”的年度G-FINDER(全球被忽视疾病创新基金 )投资报告,用于被忽视疾病(包括结核病、艾滋病病毒/艾滋病和疟疾等)研究的全球资金正处于2007年以来的最低水平。

艾滋病为啥没有疫苗? 科学家挠破头

1984 年春天, 科学家宣布已经分离出导致艾滋病的病毒 (HIV), 并预计在两年内可治愈艾滋病, 然而时间已过去 30 多年, 治疗仍遥遥无期。艾滋病已成为 21 世纪最致命的流行病, 目前估计有 3300 万人感染艾滋病病毒。医生使用强有力的药物控制人体内的艾滋病病毒来延续生命, 但艾滋病病毒导致全球死亡案例仍然数不胜数。2007 年, 约 250 万人感染了艾滋病毒, 大约相同数量的人死于

2017年2月份梅斯推荐的HIV亮点研究

人类免疫缺陷病毒(human immunodeficiency virus, HIV),即艾滋病(AIDS,获得性免疫缺陷综合征)病毒,是造成人类免疫系统缺陷的一种病毒。1983年,HIV在美国首次发现。它是一种感染人类免疫系统细胞的慢病毒(lentivirus),属逆转录病毒的一种。

Nat Microbiol:科学家有望开发新型疫苗和抗病毒药物

日前,一项刊登在国际杂志Nature Microbiology上的研究报告中,来自Sanford Burnham Prebys医学发现研究所的研究人员通过研究鉴别出了一种机体先天性免疫应答的新型调节子,这种先天性免疫反应也就是机体应对外来入侵者出现的快速天然免疫反应,相关研究或为研究人员开发新